GLP-1 medications like Ozempic and semaglutide are now used by roughly 1 in 8 US adults, concentrated in the exact 50 to 64 age range colorectal cancer screening targets. New research shows GLP-1 users face more than double the odds of inadequate bowel preparation, and clinical guidance on how to manage it is still catching up. This post breaks down the scale of GLP-1 adoption, what the data shows about its effect on prep quality, and how Zera Medical is rethinking the prep process for patients the standard approach has never served well.

Every couple of years, three of Hollywood's most recognizable comedians turn the night before their colonoscopies into a competition, complete with card games and clear gelatin. It's a funny story, but it points to something serious: bowel prep is still the single biggest reason people delay screening. This post traces the tradition from late-night television to two separate 2024 TV nods, breaks down why the dread is so universal, and looks at how ZeraFlow is designed to move prep out of the home for good.

A colonoscopy is only as good as the prep that comes before it, and up to a third of procedures are compromised by inadequate bowel preparation before the scope is ever advanced. This post breaks down what that failure actually costs: missed lesions, repeat procedures, destabilized clinic schedules, and real erosion in screening economics. It makes the case that inadequate prep is a structural problem built into the at-home model, not a patient failure, and points to ZeraFlow as a clinic-based way to fix it at the source.